Michael G. Rinaldi

Q: What Schools Are Affiliated With Michael G. Rinaldi

Michael G. Rinaldi is affiliated with the following schools: University of Scranton, University of Texas Medical Branch, University of Sheffield, Yale University, MD Anderson Cancer Center, University of Texas Health Science Center at San Antonio, Albert Einstein College of Medicine, University of Southern California, Virginia Commonwealth University, Baylor College of Medicine

Michael G. Rinaldi's AcademicInfluence.com Rankings

Michael G. Rinaldi

Philosophy

#5774

World Rank

#8669

Historical Rank

Logic

#2991

World Rank

#4081

Historical Rank

philosophy Degrees

Michael G. Rinaldi

Biology

#7766

World Rank

#10736

Historical Rank

Microbiology

#387

World Rank

#439

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Michael G. Rinaldi's Degrees

PhD Microbiology University of California, Berkeley
Doctorate Medicine University of California, San Francisco

Why Is Michael G. Rinaldi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael G. Rinaldi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. (1991) (936)
Resistance of Candida species to fluconazole (1995) (904)
Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. (2009) (843)
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora (1997) (840)
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. (1996) (797)
Infections Caused by Scedosporium spp (2008) (624)
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges (2001) (438)
Multicenter evaluation of four methods of yeast inoculum preparation (1988) (437)
Molecular Phylogenetic Diversity, Multilocus Haplotype Nomenclature, and In Vitro Antifungal Resistance within the Fusarium solani Species Complex (2008) (390)
Disseminated phaeohyphomycosis: review of an emerging mycosis. (2002) (358)
Internet-Accessible DNA Sequence Database for Identifying Fusaria from Human and Animal Infections (2010) (352)
Primary central nervous system phaeohyphomycosis: a review of 101 cases. (2004) (333)
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients (1993) (331)
In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes (2002) (326)
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B (1990) (303)
Pharmacokinetics of itraconazole following oral administration to normal volunteers (1988) (282)
Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints (2006) (272)
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. (1994) (272)
In Vitro Amphotericin B Resistance in Clinical Isolates of Aspergillus terreus, with a Head-to-Head Comparison to Voriconazole (1999) (266)
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests (1992) (254)
Zygomycosis in Solid Organ Transplant Recipients in a Tertiary Transplant Center and Review of the Literature (2006) (253)
In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents (2007) (243)
Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. (2003) (235)
Antifungal susceptibility testing (1993) (234)
Results from the ARTEMIS DISK Global AntifungalSurveillance Study: a 6.5-Year Analysis of Susceptibilitiesof Candida and Other Yeast Species to Fluconazole andVoriconazole by Standardized Disk Diffusion Testing (2005) (234)
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi (1997) (232)
Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 (2007) (230)
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. (1998) (227)
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents (2000) (225)
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document) (2010) (220)
Novel Multilocus Sequence Typing Scheme Reveals High Genetic Diversity of Human Pathogenic Members of the Fusarium incarnatum-F.equiseti and F. chlamydosporum Species Complexes within the United States (2009) (215)
Itraconazole treatment of phaeohyphomycosis. (1990) (215)
Genetic Diversity of Human Pathogenic Members of the Fusarium oxysporum Complex Inferred from Multilocus DNA Sequence Data and Amplified Fragment Length Polymorphism Analyses: Evidence for the Recent Dispersion of a Geographically Widespread Clonal Lineage and Nosocomial Origin (2004) (212)
Spectrum of Clinically Relevant Exophiala Species in the United States (2007) (208)
Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study (2002) (208)
Detection of Candida dubliniensis in Oropharyngeal Samples from Human Immunodeficiency Virus-Infected Patients in North America by Primary CHROMagar Candida Screening and Susceptibility Testing of Isolates (1998) (208)
Collaborative investigation of variables in susceptibility testing of yeasts (1990) (194)
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis (1994) (193)
In Vitro Interaction of Caspofungin Acetate with Voriconazole against Clinical Isolates of Aspergillus spp (2002) (190)
Emerging agents of phaeohyphomycosis: pathogenic species of Bipolaris and Exserohilum (1986) (184)
Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species (2004) (177)
The acute hemodynamic effects of MitraClip therapy. (2011) (176)
Importance of Candida species other than Candida albicans as opportunistic pathogens. (1998) (173)
Guide to Clinically Significant Fungi (1998) (159)
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. (1992) (156)
Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models (1998) (155)
Three distinct genotypes within Candida parapsilosis from clinical sources (1995) (151)
Fluconazole-resistant Candida albicans. (1993) (148)
Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing (1995) (147)
Optimal Testing Conditions for Determining MICs and Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Uncommon Molds: NCCLS Collaborative Study (2002) (146)
Spectrum of Zygomycete Species Identified in Clinically Significant Specimens in the United States (2009) (144)
International and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and Voriconazole (2005) (144)
Multicenter Comparison of the VITEK 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Amphotericin B, Flucytosine, and Voriconazole against Candida spp (2007) (144)
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard (1994) (141)
High-dose itraconazole in the treatment of severe mycoses (1991) (137)
Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. (1998) (136)
Immunologic susceptibility to chronic dermatophytosis. (1974) (136)
Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. (1999) (135)
Interpretation of Trailing Endpoints in Antifungal Susceptibility Testing by the National Committee for Clinical Laboratory Standards Method (1998) (134)
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii (1995) (131)
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine (1995) (130)
Development and Validation of a High-Performance Liquid Chromatography Assay for Voriconazole (2003) (128)
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. (1997) (126)
Antifungal susceptibility testing: technical advances and potential clinical applications. (1997) (125)
Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole, Amphotericin B, and Caspofungin (2007) (122)
Mycoses caused by Candida lusitaniae. (1987) (122)
A clinical, mycological, and immunological survey for dermatophytosis. (1973) (120)
In vitro evaluation of voriconazole against some clinically important fungi (1997) (120)
In Vitro Antifungal Activity of Nikkomycin Z in Combination with Fluconazole or Itraconazole (1999) (117)
Sequence-Based Identification of Filamentous Basidiomycetous Fungi from Clinical Specimens: a Cautionary Note (2009) (117)
Outbreak of invasive Aspergillus infection in surgical patients, associated with a contaminated air-handling system. (2003) (115)
Emerging fungal pathogens (1989) (115)
Spectrum of Clinically Relevant Acremonium Species in the United States (2010) (115)
Elucidating the Origins of Nosocomial Infections with Candida albicans by DNA Fingerprinting with the Complex Probe Ca3 (1999) (113)
Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. (1996) (113)
Treatment of blastomycosis with itraconazole in 112 dogs. (1996) (109)
Outbreak of Invasive Mycoses Caused by Paecilomyces lilacinus from a Contaminated Skin Lotion (1996) (107)
Acquired immunity to dermatophytes. (1974) (107)
Intra- and Interlaboratory Study of a Method for Testing the Antifungal Susceptibilities of Dermatophytes (2004) (103)
Multiple Resistant Phenotypes of Candida albicansCoexist during Episodes of Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected Patients (1999) (103)
Human Curvularia infections. Report of five cases and review of the literature. (1987) (102)
In vitro activity of voriconazole against selected fungi. (1998) (102)
The role of antifungal susceptibility testing in the therapy of candidiasis. (2004) (102)
Scedosporium inflatum, an emerging pathogen (1988) (100)
Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. (1994) (99)
Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma (2000) (96)
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole (1993) (96)
In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. (2005) (95)
Use of potato flakes agar in clinical mycology (1982) (95)
Fatal cerebral mycoses caused by the ascomycete Chaetomium strumarium (1995) (93)
Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. (2004) (92)
Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. (2005) (91)
Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience (2009) (90)
Optimal Susceptibility Testing Conditions for Detection of Azole Resistance in Aspergillus spp.: NCCLS Collaborative Evaluation (2001) (89)
Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. (1994) (88)
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus (1994) (87)
Multiple Patterns of Resistance to Fluconazole in Candida glabrata Isolates from a Patient with Oropharyngeal Candidiasis Receiving Head and Neck Radiation (2003) (87)
Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: Successful combination therapy with voriconazole and terbinafine (2007) (87)
Quality Control and Reference Guidelines for CLSI Broth Microdilution Susceptibility Method (M38-A Document) for Amphotericin B, Itraconazole, Posaconazole, and Voriconazole (2005) (85)
Fatal Disseminated Trichoderma longibrachiatum Infection in an Adult Bone Marrow Transplant Patient: Species Identification and Review of the Literature (1999) (84)
Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM). (1992) (83)
Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. (2010) (83)
Standardization of antifungal susceptibility testing. (1996) (82)
Multicenter Comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp (2007) (82)
Comparison of In Vitro Activities of Voriconazole and Five Established Antifungal Agents against Different Species of Dermatophytes Using a Broth Macrodilution Method (2001) (82)
Taxonomy and phylogeny of the Fusarium dimerum species group (2009) (81)
Invasive Nattrassia mangiferae infections: case report, literature review, and therapeutic and taxonomic appraisal (1997) (81)
Standardized susceptibility testing of fluconazole: an international collaborative study (1992) (80)
Antifungal susceptibility testing. (2006) (78)
Diagnosis and Treatment of Human Mycoses (2008) (78)
Isolation and Characterization of a New Fungal Species, Chrysosporium ophiodiicola, from a Mycotic Granuloma of a Black Rat Snake (Elaphe obsoleta obsoleta) (2008) (78)
Correlation between Antifungal Susceptibilities ofCoccidioides immitis In Vitro and Antifungal Treatment with Caspofungin in a Mouse Model (2001) (78)
Molecular Phylogeny and Proposal of Two New Species of the Emerging Pathogenic Fungus Saksenaea (2010) (78)
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans (1995) (78)
U.S. Case Report of Cerebral Phaeohyphomycosis Caused by Ramichloridium obovoideum (R. mackenziei): Criteria for Identification, Therapy, and Review of Other Known Dematiaceous Neurotropic Taxa (1998) (77)
Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS (1992) (77)
Efficacy of Voriconazole in a Guinea Pig Model of Disseminated Invasive Aspergillosis (2000) (77)
Simple method for detecting fluconazole-resistant yeasts with chromogenic agar (1996) (76)
Dermatophytosis: epidemiological and microbiological update. (2000) (76)
In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens (2000) (75)
Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. (1990) (73)
Fluconazole Disk Diffusion Susceptibility Testing ofCandida Species (1998) (73)
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis (1991) (72)
Comparative evaluation of macrodilution and alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates (1995) (72)
Candida glabrata Oropharyngeal Candidiasis in Patients Receiving Radiation Treatment for Head and Neck Cancer (2002) (71)
Fluconazole tolerance in clinical isolates of Cryptococcus neoformans (1997) (71)
Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma (1994) (71)
Treatment of Histoplasmosis with MK-991 (L-743,872) (1998) (70)
In Vitro Activities of Approved and Investigational Antifungal Agents against 44 Clinical Isolates of Basidiomycetous Fungi (2001) (70)
Serotypes of Cryptococcus neoformans in patients with AIDS. (1986) (69)
Model dermatophytosis in naturally infected subjects. (1974) (69)
Aspergillus nidulans is frequently resistant to amphotericin B (2002) (69)
A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. (1998) (68)
Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. (1998) (68)
Efficacy of SCH56592 in a Rabbit Model of Invasive Aspergillosis (2000) (67)
Trichoderma longibrachiatum infection in a pediatric patient with aplastic anemia (1997) (67)
Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis (1991) (66)
Epidemiology of Oropharyngeal CandidaColonization and Infection in Patients Receiving Radiation for Head and Neck Cancer (1999) (66)
The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. (2000) (65)
In Vitro and In Vivo Activities of Posaconazole against Coccidioides immitis (2002) (65)
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates (1994) (65)
In Vitro Activities of Terbinafine in Combination with Fluconazole, Itraconazole, Voriconazole, and Posaconazole against Clinical Isolates of Candida glabrata with Decreased Susceptibility to Azoles (2002) (64)
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. (1993) (64)
Two new species of Mucor from clinical samples. (2011) (63)
SCH 56592, Amphotericin B, or Itraconazole Therapy of Experimental Murine Cerebral Phaeohyphomycosis Due toRamichloridium obovoideum (“Ramichloridium mackenziei”) (2000) (62)
Acute invasive sinusitis due to Trichoderma longibrachiatum in a liver and small bowel transplant recipient. (1998) (62)
Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer. (2003) (62)
Trichosporon mycotoxinivorans, a Novel Respiratory Pathogen in Patients with Cystic Fibrosis (2009) (62)
Problems in the diagnosis of invasive fungal diseases. (1991) (62)
Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. (1994) (62)
Invasive infection due to Apophysomyces elegans in immunocompetent hosts. (1993) (61)
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods (1994) (61)
Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. (1994) (61)
Treatment of mycotic rhinitis with itraconazole in three horses. (1994) (60)
DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. (1995) (59)
Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. (2009) (59)
Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection (1989) (58)
Invasive Mycotic Infections Caused by Chaetomium perlucidum, a New Agent of Cerebral Phaeohyphomycosis (2003) (57)
Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans. (2000) (54)
Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts (1986) (54)
Cutaneous infection in man caused by Fusarium moniliforme. (1977) (53)
Disseminated Mycotic Infection Caused by Colletotrichum acutatum in a Kemp's Ridley Sea Turtle (Lepidochelys kempi) (2002) (53)
Activity of Posaconazole against Pseudallescheria boydii: In Vitro and In Vivo Assays (2003) (51)
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole (1996) (51)
Primary invasive cutaneous Microsporum canis infections in immunocompromised patients (1996) (48)
Scedosporium apiospermum Soft Tissue Infection Successfully Treated with Voriconazole: Potential Pitfalls in the Transition from Intravenous to Oral Therapy (2005) (47)
Quality Control and Reference Guidelines for CLSI Broth Microdilution Method (M38-A Document) for Susceptibility Testing of Anidulafungin against Molds (2007) (46)
Pathogenicity and antifungal susceptibility ofChaetomium species (1995) (46)
Posaconazole Prophylaxis in Experimental Systemic Zygomycosis (2006) (45)
In Vitro Activities of New Antifungal Agents against Chaetomium spp. and Inoculum Standardization (2003) (45)
Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial. (1996) (45)
Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis (1996) (45)
Paecilomyces lilacinus catheter-related fungemia in an immunocompromised pediatric patient (1992) (44)
Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. (1995) (44)
In Vitro Antifungal Susceptibility and Molecular Characterization of Clinical Isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum (2008) (44)
Cloning and characterization of the lanosterol 14alpha-demethylase (ERG11) gene in Cryptococcus neoformans. (2004) (44)
Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection (1997) (43)
Comparison of 24-Hour and 48-Hour Voriconazole MICs as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) in Three Laboratories: Results Obtained with 2,162 Clinical Isolates of Candida spp. and Other Yeasts (2009) (43)
Disseminated Aspergillosis Caused by Aspergillus ustusin a Patient Following Allogeneic Peripheral Stem Cell Transplantation (1998) (42)
Ocular penetration and pharmacokinetics of topical fluconazole. (1997) (42)
Zygomycosis due to Mucor circinelloides in a neutropenic patient receiving chemotherapy for acute myelogenous leukemia. (1994) (41)
Systemic availability of itraconazole in lung transplantation (1996) (41)
Interlaboratory Study of Quality Control Isolates for a Broth Microdilution Method (Modified CLSI M38-A) for Testing Susceptibilities of Dermatophytes to Antifungals (2006) (41)
Cutaneous Infection Caused by Macrophomina phaseolina in a Child with Acute Myeloid Leukemia (2009) (41)
Invasive hyalohyphomycosis caused by Scopulariopsis brevicaulis in a patient undergoing allogeneic bone marrow transplant. (1989) (40)
Identification and First Report of Inonotus (Phellinus) tropicalis as an Etiologic Agent in a Patient with Chronic Granulomatous Disease (2005) (40)
Human Phaeohyphomycotic Osteomyelitis Caused by the Coelomycete Phomopsis Saccardo 1905: Criteria for Identification, Case History, and Therapy (1999) (40)
Comparison of Visual 24-Hour and Spectrophotometric 48-Hour MICs to CLSI Reference Microdilution MICs of Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Candida spp.: a Collaborative Study (2005) (40)
Transplant‐associated Ochroconis gallopava infections (2008) (40)
Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. (1995) (40)
Disseminated hyalohyphomycosis caused by a novel human pathogen, Fusarium napiforme (1993) (39)
Experimental murine chromomycosis mimicking chronic progressive human disease. (1989) (39)
Metarrhizium anisopliae as a Cause of Sinusitis in Immunocompetent Hosts (1999) (39)
In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of (1999) (39)
Patterns of morphologic variation among isolates of Trichosporon beigelii (1990) (39)
Paecilomyces lilacinus Vaginitis in an Immunocompetent Patient (2003) (38)
In Vitro and In Vivo Activities of Posaconazole and Amphotericin B in a Murine Invasive Infection by Mucor circinelloides: Poor Efficacy of Posaconazole (2012) (38)
Identification of Exophiala mesophila Isolated from Treated Dental Unit Waterlines (2003) (38)
Bipolaris hawaiiensis-caused phaeohyphomycotic orbitopathy. A devastating fungal sinusitis in an apparently immunocompetent host. (1989) (38)
Opportunistic mycotic infection caused by chaetomium in a patient with acute leukemia (1983) (38)
Feline brain abscesses due to Cladosporium trichoides. (1977) (37)
Assay of fluconazole by high-performance liquid chromatography with a mixed-phase column (1992) (37)
Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates. (1994) (37)
In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against Candida glabrata (2004) (37)
Invasive aspergillosis. (1983) (36)
Continuous ambulatory peritoneal dialysis complicated by Aureobasidium pullulans peritonitis. (1995) (36)
STEADY-STATE PLASMA CONCENTRATIONS OF ITRACONAZOLE AFTER ORAL ADMINISTRATION IN KEMP'S RIDLEY SEA TURTLES, LEPIDOCHELYS KEMPI (2009) (35)
DNA fingerprinting of Candida rugosa via repetitive sequence-based PCR (1996) (35)
Acrophialophora fusispora Brain Abscess in a Child with Acute Lymphoblastic Leukemia: Review of Cases and Taxonomy (2000) (35)
Fungemia caused by an amphotericin B-resistant isolate of Sporothrix schenckii. Successful treatment with itraconazole. (1989) (34)
Molecular and Phenotypic Characterization of Phialemonium and Lecythophora Isolates from Clinical Samples (2011) (34)
Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study (1996) (34)
Endocarditis and hip arthritis associated with Scedosporium inflatum. (1990) (34)
Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values. (2013) (34)
Uncommon invasive fungal pathogens in the acquired immunodeficiency syndrome. (1993) (34)
Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans (1996) (34)
Disseminated sporotrichosis in a patient infected with human immunodeficiency virus. (1992) (33)
Candida dubliniensis in radiation-induced oropharyngeal candidiasis. (2001) (33)
Correlation between InVitro Activity of Posaconazole and InVivo Efficacy against Rhizopus oryzae Infection in Mice (2010) (33)
Disseminated Fusarium moniliforme infection after allogeneic marrow transplantation. (1986) (33)
Office practice-based confirmation of onychomycosis: a US nationwide prospective survey. (2002) (33)
Disseminated Microascus cirrosus infection in pediatric bone marrow transplant recipient (1995) (32)
Exophiala oligosperma Causing Olecranon Bursitis (2003) (32)
Accelerated Metabolism of Voriconazole and Its Partial Reversal by Cimetidine (2009) (32)
Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. (2008) (32)
Multicenter Comparison of the Vitek 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Caspofungin, Micafungin, and Posaconazole against Candida spp (2011) (31)
Pulmonary Infection Caused by Gymnascella hyalinospora in a Patient with Acute Myelogenous Leukemia (2000) (31)
Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis (1993) (31)
Evaluation of pulsed-field gel electrophoresis as a typing system for Candida rugosa: comparison of karyotype and restriction fragment length polymorphisms (1996) (30)
An Unusual Case of Fungal Keratitis: Metarrhizium anisopliae (2001) (30)
Bronchoscopic and serologic diagnosis of Aspergillus fumigatus pulmonary infection in a bottlenose dolphin (Tursiops truncatus). (1998) (30)
In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten‐year period against fluconazole, voriconazole and posaconazole (SCH56592) (2002) (30)
Trailing end-point phenotype of Candida spp. in antifungal susceptibility testing to fluconazole is eliminated by altering incubation temperature. (2007) (29)
Antifungal susceptibility testing. Current state of technology, limitations, and standardization. (1993) (28)
Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model (1996) (28)
Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients. (1995) (28)
Phaeohyphomycotic cutaneous disease caused by Pleurophoma in a cardiac transplant patient. (1989) (27)
Hyphal forms in the central nervous system of patients with coccidioidomycosis. (2000) (27)
Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination (1991) (27)
Normally saprobic cryptococci isolated from Cryptococcus neoformans infections (1991) (27)
In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum (1990) (27)
Severe hepatitis associated with ketoconazole therapy for chronic mucocutaneous candidiasis. (1982) (26)
Caspofungin in Combination with Amphotericin B against Candida glabrata (2005) (26)
Fungal peritonitis caused by Lecythophora mutabilis (1985) (26)
Comparative Evaluation of National Committee for Clinical Laboratory Standards Broth Macrodilution and Agar Dilution Screening Methods for Testing Fluconazole Susceptibility ofCryptococcus neoformans (1998) (26)
Candida and Torulopsis: a blinded evaluation of use of pseudohypha formation as basis for identification of medically important yeasts (1997) (25)
Pseudoepidemic of Aspergillus niger Infections Traced to Specimen Contamination in the Microbiology Laboratory (1999) (25)
Micafungin Concentrations from Brain Tissue and Pancreatic Pseudocyst Fluid (2010) (24)
Fatal disseminated infection caused by Myceliophthora thermophila, a new agent of mycosis: case history and laboratory characteristics (1992) (23)
Some medically important fungi and their common synonyms and names of uncertain application. (1999) (23)
Posaconazole Treatment for Apophysomyces elegans Rhino-Orbital Zygomycosis following Trauma for a Male with Well-Controlled Diabetes (2007) (23)
First U.S. Report of Subcutaneous Phaeohyphomycosis Caused by Veronaea botryosa in a Heart Transplant Recipient and Review of the Literature (2004) (23)
Demonstration, by immunoelectronmicroscopy, of a cell wall antigen in Trichosporon beigelii that cross-reacts with Cryptococcus neoformans capsular polysaccharide. (1988) (23)
Itraconazole-didanosine excipient interaction. (1993) (23)
Laboratory evaluation of antifungal agents: a brief overview. (1992) (23)
Total synthesis and antifungal activity of a carbohydrate ring-expanded pyranosyl nucleoside analogue of nikkomycin B. (2007) (22)
Cutaneous Infection Caused by Cylindrocarpon lichenicola in a Patient with Acute Myelogenous Leukemia (2000) (22)
Amphotericin B in the treatment of Candida cholecystitis. (1989) (22)
Pharmacokinetics of Anidulafungin in Pleural Fluid during the Treatment of a Patient with Candida Empyema (2011) (21)
Combination Therapy with Terbinafine and Amphotericin B in a Rabbit Model of Experimental Invasive Aspergillosis (2005) (21)
Fungal maxillary sinusitis caused by Curvularia lunata. (1987) (21)
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. (1999) (20)
Coccidioides immitis presenting as a mycelial pathogen with empyema and hydropneumothorax. (1992) (20)
Apparent cross-reactivity of airborne molds and the dermatophytic fungi. (1973) (20)
TCT-21 Use of IVUS Reduces Stent Thrombosis: Results from the Prospective, multicenter ADAPT-DES Study (2012) (19)
Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis (1995) (19)
Traumatic joint infection due to Geotrichum candidum. (1995) (19)
Fatal Hormonema dematioides Peritonitis in a Patient on Continuous Ambulatory Peritoneal Dialysis: Criteria for Organism Identification and Review of Other Known Fungal Etiologic Agents (1998) (19)
Cerebral Aspergillosis Caused by Aspergillus granulosus (2009) (18)
Isolated endogenous endophthalmitis due to a sporodochial-forming Phialemonium curvatum acquired through intracavernous autoinjections. (2006) (18)
Acremonium falciforme as a cause of mycetoma in California. (1976) (18)
Susceptibilities of Clinical and Laboratory Isolates of Blastomyces dermatitidis to Ketoconazole, Itraconazole, and Fluconazole (1998) (18)
Cutaneous phaeohyphomycosis caused by a rare fungal pathogen, Hormonema dematioides: successful treatment with ketoconazole. (1990) (18)
Scedosporium inflatum osteomyelitis in a dog (1992) (17)
Primary lymphocutaneous Nocardia brasiliensis infection: three case reports and a review of the literature. (1988) (17)
Bilateral Pulmonary Aspergilloma Caused by an Atypical Isolate of Aspergillus terreus (2000) (17)
Persistent pulmonary infection with an azole-resistant Coccidioides species. (2008) (17)
Magnetic resonance imaging findings in fatal primary cerebral infection due to Chaetomium strumarium. (2005) (17)
Efficacies of Amphotericin B (AMB) Lipid Complex, AMB Colloidal Dispersion, Liposomal AMB, and Conventional AMB in Treatment of Murine Coccidioidomycosis (2004) (16)
Rhizopus schipperae, sp. nov., a new agent of zygomycosis (1996) (16)
Cokeromyces recurvatus Poitras, a distinctive zygomycete and potential pathogen: Criteria for identification (1990) (16)
Further Characterization of Human Salivary Anticandidal Activities in a Human Immunodeficiency Virus-Positive Cohort by Use of Microassays (1999) (16)
Correlation of Susceptibility of Cryptococcus neoformans to Amphotericin B with Clinical Outcome (2011) (16)
Nomenclature of fungal diseases (1992) (16)
A comparison between fluconazole tablets and clotrimazole troches for the treatment of thrush in HIV infection. (1992) (15)
A Novel Case of Fusarium oxysporum Infection in an Atlantic Bottlenose Dolphin (Tursiops truncatus) (2010) (15)
Pharmacokinetics of Liposomal Amphotericin B in Pleural Fluid (2010) (15)
Phaeohyphomycotic cyst caused by a recently described species, Phaeoannellomyces elegans (1987) (14)
Bleomycin therapy of experimental disseminated candidiasis in mice (1996) (14)
In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus (1994) (14)
Candida parapsilosis: An emerging problem (1988) (13)
Diagnosis and Treatment of Fungal Infections (2015) (13)
Cutaneous infection with Metarhizium anisopliae in a patient with hypohidrotic ectodermal dysplasia and immune deficiency. (2008) (13)
Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer (2002) (13)
Cokeromyces recurvatus isolated from pleural and peritoneal fluid: case report (1996) (13)
Pulmonary Phialemonium curvatum phaeohyphomycosis in a Standard Poodle dog. (2008) (13)
Enteral fluconazole is well absorbed in critically ill surgical patients. (2002) (13)
Descriptive statistical analyses of serial dilution data. (1988) (13)
CHAPTER 14 – Dematiaceous fungi (2009) (12)
Epidemiology of mycoses in the HIV-infected patient: clinical aspects. (1996) (12)
High mortality in a large-scale zebrafish colony (Brachydanio rerio Hamilton & Buchanan, 1822) associated with Lecythophora mutabilis (van Beyma) W. Gams & McGinnis. (2001) (12)
Confirmation of dermatophytes in nail specimens using in-office dermatophyte test medium cultures. Insights from a multispecialty survey. (2003) (12)
Quality Control Limits for Fluconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue (2003) (12)
Efficacy of Caspofungin against Aspergillus terreus (2005) (12)
In Vitro-Clinical Correlations for Amphotericin B Susceptibility in AIDS-Associated Cryptococcal Meningitis (2006) (12)
Antifungal drug susceptibility testing. (1994) (11)
Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates (1990) (11)
Gluteal abscess caused by Phialophora hoffmannii and review of the role of this organism in human mycoses (1982) (11)
Emerging opportunists. (1989) (11)
A corneal abscess due to the fungus Botryodiplodia theobromae. (1975) (11)
Bipolaris-Caused Fungal Sinusitis (1992) (11)
Discrepancy between in vitro and in vivo antifungal activity of albendazole. (1997) (10)
In Vitro Activities of Free and Lipid Formulations of Amphotericin B and Nystatin against Clinical Isolates of Coccidioides immitis at Various Saprobic Stages (2002) (10)
Comparison of Antifungal Susceptibilities to Fluconazole and Voriconazole of Oral Candida glabrata Isolates from Head and Neck Radiation Patients (2004) (10)
Treatment of thrush with itraconazole solution: evidence for topical effect. (1998) (10)
Treatment of coccidioidomycosis with SCH 39304. (1994) (10)
Comparison of SCH 39304 and its isomers, RR 42427 and SS 42426, for treatment of murine cryptococcal and coccidioidal meningitis (1992) (10)
Identification of intracellular proteases from Nocardia brasiliensis (1992) (9)
MIC Values of Voriconazole Are Predictive of Treatment Results in Murine Infections by Aspergillus terreus Species Complex (2013) (9)
AngioJet experience from the multi-center STENT Registry. (2006) (9)
Selected medically important fungi and some common synonyms and obsolete names. (1995) (9)
An aberrant variant of Histoplasma capsulatum var. capsulatum (1997) (9)
The relationship of oral Candida tropicalis infection to systemic candidiasis in a patient with leukemia. (1988) (9)
Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304. (1990) (8)
Mycotic flora of the interdigital spaces of the human foot: A preliminary investigation (1975) (8)
Quality Control Limits for Voriconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue (2004) (8)
Treatment of vaginal candidiasis with ketoconazole. (1983) (8)
THE EVEREST II HIGH SURGICAL RISK COHORT: EFFECTIVENESS OF TRANSCATHETER REDUCTION OF SIGNIFICANT MITRAL REGURGITATION IN HIGH SURGICAL RISK PATIENTS (2013) (8)
Comparison of D0870 and fluconazole in the treatment of murine cryptococcal meningitis. (1995) (8)
Relationship between metabolism and biomass of medically important zygomycetes. (2006) (8)
IN VITRO SUSCEPTIBILITY OF DERMATOPHYTES TO ANTIEUNGAL DRUGS (1993) (7)
Fusarium and the immunocompromised host: liaisons dangeureuses. (1990) (7)
Disseminated aspergillosis in a dog. (1978) (7)
FINAL RESULTS OF THE EVEREST II RANDOMIZED CONTROLLED TRIAL OF PERCUTAENOUS AND SURGICAL REDUCTION OF MITRAL REGURGITATION (2014) (6)
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. (2006) (6)
Amphotericin B Enzyme-Linked Immunoassay for Clinical Use: Comparison with Bioassay and HPLC (1997) (6)
Evaluation of the correlation of caspofungin MICs and treatment outcome in murine infections by wild type strains of Candida parapsilosis. (2013) (6)
Resistance ofCandidaSpecies to Fluconazole (1995) (6)
Some medically important fungi and their common synonyms and obsolete names. (1997) (5)
Reduction and Growth Inhibition of Microorganisms in Commercial and Institutional Environments (1995) (5)
EVEREST II REALISM - A CONTINUED ACCESS STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE MITRACLIP DEVICE: ANALYSIS OF RESULTS THROUGH 1 YEAR (2015) (4)
Spontaneous lysis of mycetomas after acute cavitating lung disease. (1981) (4)
The Evollving Etiologies of invasive Mycoses (1994) (4)
Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis? (2012) (4)
Controversies in medical mycology. (1997) (4)
Selected medically important fungi with common synonyms and other obsolete names. (1993) (3)
Serotypes of Cryptococcus neoformans in Patients (1986) (3)
Penicillium janthinellum in sputum and bronchoalveolar lavage in an AIDS patient with pneumonia. (1997) (3)
Dissitimurus, a new dematiaceous genus of Hyphomycetes (1987) (3)
STENT EXPANSION MODELS TO PREDICT CLINICAL OUTCOME: AN IVUS SUBSTUDY FROM ADAPT-DES (2020) (3)
Histoplasma in AIDS Patients (1990) (2)
TCT-91 1-Year Outcomes From the Multicenter, Prospective Study With the Novel PASCAL Transcatheter Valve Repair System for Patients With Mitral Regurgitation in the CLASP Study (2019) (2)
Antiplatelets and AntithrombinsTCT-157 The Effect of Smoking Status on Platelet Reactivity and Long-Term Events after PCI. Does a Clopidogrel-related "Smoker's paradox" Exist? (2013) (2)
Comparative evaluation of macrodilution and chromogenic agar dilution screening for fluconazole susceptibility of Candida albicans (1996) (2)
THE EVEREST II REALISM CONTINUED ACCESS STUDY: EFFECTIVENESS OF TRANSCATHETER REDUCTION OF SIGNIFICANT MITRAL REGURGITATION IN SURGICAL CANDIDATES (2013) (2)
LONG-TERM CLINICAL IMPACT OF ACUTE STENT MALAPPOSITION: AN ADAPT-DES IVUS SUBSTUDY (2014) (2)
Pharmacokinetics of SCH-39304 in human immunodeficiency virus-infected patients following chronic oral dosing (1992) (2)
Primary Invasive CutaneousMicrosporum canisInfections in Immunocompromised Patients (1996) (2)
Studies on peptidyl nucleoside antibiotics: synthesis and antifungal evaluation of pyranosyl nucleoside analogs of nikkomycin. (2009) (2)
An Unusual Case of Fungal Keratitis (2001) (2)
5-YEAR DURABILITY RESULTS OF TRANSCATHETER MITRAL VALVE REPAIR WITH THE MITRACLIP® SYSTEM IN PATIENTS WITH SEVERE DEGENERATIVE MITRAL REGURGITATION AND PROHIBITIVE SURGICAL RISK (2018) (2)
In Vitro Activity of a New Antifungal Triazole , D 0870 , against Candida albicans Isolates from Oral Cavities of Patients Infected with Human Immunodeficiency Virus (2)
Six-month Outcomes from the Multicenter, Prospective Study with the Novel PASCAL Transcatheter Valve Repair System for Patients with Mitral Regurgitation in the CLASP Study (2019) (2)
CLINICAL IMPACT OF ATTENUATED PLAQUE AFTER STENT IMPLANTATION: AN ADAPT-DES IVUS SUBSTUDY (2014) (1)
Dermatophytosis : Epidemiological and microbiological update. Discussion (2000) (1)
DNA fingerprinting of Candida rugosa via (1996) (1)
TCT CONNECT-342 Outcomes of MitraClip Repair in Primary Mitral Regurgitation Patients With STS Repair Score of Less Than 6% and STS Replacement Score of Less Than 8%: Results From the Global EXPAND Study (2020) (1)
Introduction: The Evolving Etiologies of Invasive Mycoses (1994) (1)
In vitro activity of amphotericin B , fluconazole , and XMP445 against clinical isolates of Fusarium species (1999) (1)
Abstract 3789: Reverse Remodeling of the Left Ventricle after Percutaneous Mitral Valve Repair Using the Evalve MitraClip Device (2006) (1)
OUTCOMES OF TRANSCATHETER MITRAL VALVE REPAIR IN PATIENTS WITH SECONDARY MITRAL REGURGITATION ACCORDING TO THE SEVERITY OF LEFT VENTRICULAR DYSFUNCTION: THE COAPT TRIAL (2020) (1)
TCT-20 IVUS Predictors of Stent Thrombosis: Results From the Prospective, Multicenter ADAPT-DES Study (2012) (1)
ETIOLOGY, TIMING AND IMPACT OF DUAL ANTIPLATELET THERAPY DISCONTINUATION AFTER DRUG-ELUTING STENT IMPLANTATION: INSIGHTS FROM THE ADAPT-DES STUDY (2016) (1)
PLATELET REACTIVITY AND CLINICAL OUTCOMES AFTER CORONARY ARTERY IMPLANTATION OF DRUG-ELUTING STENTS IN SUBJECTS WITH PERIPHERAL ARTERIAL DISEASE: ANALYSIS FROM THE ADAPT-DES STUDY (2014) (1)
MYOCARDIAL BRIDGING DOES NOT AFFECT ATHEROSCLEROSIS IN ADJACENT CORONARY ARTERY SEGMENTS: AN ADAPT–DES IVUS SUB–STUDY (2013) (1)
LONG-TERM CLINICAL IMPACT OF CONTRAST-ASSOCIATED ACUTE KIDNEY INJURY FOLLOWING PCI AN ADAPT-DES SUB-STUDY (2021) (1)
4176The EVEREST II REALISM continued access non-high risk study: mid- and long-term follow-up in surgical candidates (2017) (1)
IMPACT OF POINT-OF-CARE PLATELET FUNCTION TESTING AMONG DIABETIC AND NON-DIABETIC PATIENTS UNDERGOING PCI WITH DRUG-ELUTING STENTS: AN ADAPT-DES SUBSTUDY (2012) (1)
TCT-253 Calling 911 Anywhere Best Determines Reduction in Total Ischemia Time in ST-Elevation Myocardial Infarction (STEMI) (2013) (1)
Prophylaxis for Cryptococcal Infection in AIDS Patients with CD4 Cell Counts of (1996) (1)
EFFECT OF HIGH PLATELET REACTIVITY ON ADVERSE EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION FOR LEFT MAIN CORONARY ARTERY DISEASE: THE ADAPT-DES STUDY (2020) (0)
PLATELET REACTIVITY AND OUTCOMES AFTER PCI OF SAPHENOUS VEIN GRAFTS VERSUS NATIVE CORONARY ARTERIES: THE ADAPT-DES STUDY (2017) (0)
TCT-352 Proportion of Ischemic Risk After PCI Mediated by High Platelet Reactivity on Clopidogrel: Analysis From the ADAPT-DES Study. (2016) (0)
OUTBREAK OF ASPERGILLUS INFECTIONS CAUSED BY A CONTAMINATED AIR- HANDLING SYSTEM IN A HOSPITAL OPERATING THEATER (2013) (0)
TCT CONNECT-5 Six-Month and One-Year Outcomes for Transcatheter Repair in Patients With Mitral Regurgitation From the CLASP Study (2020) (0)
Posaconazole Prophylaxis in Experimental Systemic Zygomycosis (cid:1) (2006) (0)
TCT-353 Underweight Status, Platelet Reactivity, and 2-Year Clinical Outcomes in Patients Undergoing PCI With DES: An ADAPT-DES Study Analysis. (2016) (0)
CLINICAL IMPACT OF TISSUE PROTRUSION AFTER STENT IMPLANTATION: AN ADAPT-DES IVUS SUBSTUDY (2014) (0)
TCT-732 Relationship Between Stent Diameter, Platelet Reactivity, and Adverse Events After PCI: Analysis from the ADAPT-DES study. (2017) (0)
, Deanna Susceptibility to Azoles with Decreased Candida glabrata Posaconazole against Clinical Isolates of Itraconazole , Voriconazole , and Combination with Fluconazole , In Vitro Activities of Terbinafine in (2002) (0)
TCT-296 Impact of Baseline Positive Coronary Artery Remodeling on 2-year Outcomes after IVUS-guided PCI: The ADAPT-DES IVUS Sub-Study (2017) (0)
Current Topic : Review vow . 8 , No . 4 (0)
Phaeohyphomycosis and Hyalohyphomycosis (2000) (0)
DOES CALCIUM BURDEN IMPACT ON CULPRIT LESION MORPHOLOGY AND CLINICAL (2015) (0)
Comparison ofSCH39304 andItsIsomers, RR 42427andSS42426, forTreatment ofMurineCryptococcal andCoccidioidal Meningitis (1992) (0)
TCT-72 PCI Lesion Morphology According to Chronic Statin Use: An ADAPT-DES IVUS Substudy (2013) (0)
eight-center collaborative study. neoformans with and without agitation: an of Candida albicans and Cryptococcus Microdilution antifungal susceptibility testing (2013) (0)
TCT-8 Impact of Aspirin Resistance on Outcomes after Coronary Events. (2016) (0)
TCT-671 Relationship Between Plaque Morphologies And Clinical Presentation In The ADAPT-DES IVUS Substudy (2013) (0)
TCT CONNECT-344 Transcatheter Mitral Valve Repair or Medical Therapy for Severe Functional Mitral Regurgitation in Women Compared With Men: The COAPT Trial (2020) (0)
Correlation of predominance of fluconazole-resistant isolates and response to therapy in recurrent oropharyngeal candidiasis in HIV-infected patients (1997) (0)
Abstract 1698: Significant Reverse Remodeling of the Left Ventricle One Year After Percutaneous Mitral Repair with the MitraClipTM Device in Patients with Pre-existing Systolic LV Dysfunction. (2007) (0)
FOCUS Antifungal Susceptibility Testing: Practical Aspects and Current Challenges (2001) (0)
Immunodeficiency Virus-Infected Patients Oropharyngeal Candidiasis in Human Coexist during Episodes of albicans Candida Multiple Resistant Phenotypes of (1999) (0)
Ketoconazole, Itraconazole, and Fluconazole Isolates of Blastomyces dermatitidis to Susceptibilities of Clinical and Laboratory (2013) (0)
TCT-7 Relationship Between Traditional Risk Factors, Platelet Reactivity, and Thrombotic Events: A Mediation Analysis From ADAPT-DES. (2016) (0)
DO EARLY CHANGES IN LEFT VENTRICULAR EJECTION FRACTION PREDICT LONG-TERM OUTCOMES AFTER TRANSCATHETER MITRAL VALVE REPAIR OF SECONDARY MITRAL REGURGITATION? THE COAPT TRIAL (2020) (0)
Office Practice-Based Confirmation of Onychomycosis (2017) (0)
IMPACT OF POSITIVE AND NEGATIVE CORONARY REMODELING ON CULPRIT LESION MORPHOMETRY: THE ADAPT–DES IVUS SUBSTUDY (2013) (0)
Current topics in medical mycology. Volume 4. (1992) (0)
TCT-1 Do Proton Pump Inhibitors Interact With Clopidogrel? Insights From ADAPT-DES (2013) (0)
Determination of SCH 39304 by megabore capillary gas-liquid chromatography. (1994) (0)
RELATIONSHIP BETWEEN PLATELET REACTIVITY AND CULPRIT AND NON–CULPRIT LESION MORPHOLOGY: THE ADAPT–DES IVUS SUBSTUDY (2013) (0)
LACK OF ASSOCIATION BETWEEN ON–TREATMENT PLATELET REACTIVITY AND ISCHEMIC OUTCOMES IN DIABETIC PATIENTS: ONE YEAR RESULTS OF THE ADAPT–DES STUDY (2013) (0)
TCT-155 The Interaction Between Clopidogrel and Calcium Channel Blockers on Platelet Reactivity and Long-Term Events after PCI (2013) (0)
TCT-93 Percutaneous Reduction of Severe Mitral Regurgitation in Elderly High Surgical Risk Patients (2013) (0)
Stability and sterility of iv fluconazole in glass units and plastic viaflex containers (1992) (0)
Deanna A. Sutton, Annette W. Fothergill and Michael G. Rinaldi, it Guide to Clinically Significant Fungi (2004) (0)
TCT-420 Derivation and External Validation of a Novel Risk Score for Prediction of 30-Day Mortality After Percutaneous Coronary Intervention (2019) (0)
TCT-669 Differences in Culprit Lesion Plaque Stability between Males and Females: A VH-IVUS Analysis from the ADAPT-DES Study (2013) (0)
IMPACT OF SMALL DEVICE USE IN THE PROXIMAL LAD VERSUS OTHER CORONARY SEGMENTS ON LONG-TERM CLINICAL OUTCOMES: AN ADAPT-DES SUB-ANALYSIS (2018) (0)
Comparative evaluation of NCCLS macrobroth and agar dilution screening for fluconazole susceptibility of Cryptococcus neoformans (1997) (0)
TCT-597 Predictors of Stent Expansion After Drug-eluting Stents: An ADAPT-DES IVUS substudy (2013) (0)
PREDICTORS OF CLINICAL SUPER-RESPONDERS IN THE COAPT TRIAL (2020) (0)
Fungal infection in a cat caused by an unusual etiology acremonium kiliense (1985) (0)
Correlation between In Vitro Activity of Posaconazole and In Vivo Efﬁcacy against Rhizopus oryzae Infection in Mice (cid:1) (2010) (0)
TCT-667 Relationship Between Renal Function and Lesion Morphology: An ADAPT-DES VH-IVUS sub-study (2013) (0)
Diffusion Testing Voriconazole by Standardized Disk Other Yeast Species to Fluconazole and and Candida Analysis of Susceptibilities of Antifungal Surveillance Study: a 6.5-Year Results from the ARTEMIS DISK Global (2014) (0)
IMPACT OF RENAL DYSFUNCTION ON OUTCOMES IN PATIENTS WITH SECONDARY MITRAL REGURGITATION: RESULTS FROM THE COAPT TRIAL (2020) (0)
The changing mycology of candidiasis: new and resistant pathogens. (1997) (0)
experimental murine candidiasis model. cavities of patients with AIDS in an albicans strains sequentially isolated from oral Variation in fluconazole efficacy for Candida (2013) (0)
Bipolaris hawaiiensis—caused Phaeohyphomycotic Orbitopathy. A Devastating Fungal Sinusitis in an Apparently Immunocompetent Host (1990) (0)
Cerebral Aspergillosis Caused by Aspergillus granulosus (cid:1) (2009) (0)
INCIDENCE, FEATURES, AND OUTCOMES OF EDGE DISSECTION AFTER DRUG-ELUTING STENT IMPLANTATION: AN ADAPT-DES IVUS SUB-STUDY (2014) (0)
DIFFERENTIAL IMPACT OF HIGH PLATELET REACTIVITY ON CLOPIDOGREL IN WOMEN AND MEN FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) WITH DES (2015) (0)
TCT-166 Correlates of High Platelet Reactivity on Clopidogrel in 8,533 Patients: An ADAPT-DES Substudy (2013) (0)
TCT-733 Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After PCI: Analysis from the ADAPT-DES study (2017) (0)
TCT-400 Platelet Reactivity and Risk of Stent Thrombosis After Coronary Drug-Eluting Stent Implantation in Patients Treated With Oral Anticoagulation: The ADAPT-DES Study (2019) (0)
In Vitro and In Vivo Activities of Posaconazole and Amphotericin B in a Murine Invasive Infection by Mucor circinelloides : Poor Efﬁcacy of Posaconazole (2012) (0)
Cryptococcus neoformans var. neoformans. fluconazole and flucytosine against In vitro evaluation of combination of (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael G. Rinaldi?

Michael G. Rinaldi is affiliated with the following schools:

Michael G. Rinaldi's Academic­Influence.com Rankings

Michael G. Rinaldi's Degrees

Why Is Michael G. Rinaldi Influential?

Michael G. Rinaldi's Published Works

Published Works

What Schools Are Affiliated With Michael G. Rinaldi?

Michael G. Rinaldi's AcademicInfluence.com Rankings